Novel treatment options in depression and psychosis

References

• DemyttenaereKBruffaertsRPosada-VillaJPrevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health SurveysJAMA20042912581259015173149
   PubMed Web of Science ®Google Scholar
• Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015Lancet20163881545160227733282
   PubMed Web of Science ®Google Scholar
• RiefWBarskyAJBingelURethinking psychopharmacotherapy: the role of treatment context and brain plasticity in antidepressant and antipsychotic interventionsNeurosci Biobehav Rev201660516426616735
   PubMed Web of Science ®Google Scholar
• AlysonJMcGregorAJThe effects of sex and gender on pharmacologic toxicity: implications for clinical therapyClin Ther2017398928034520
   PubMed Web of Science ®Google Scholar
• HiemkeCBaumannPBergemannNAGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011Pharmacopsychiatry201144195235
   Web of Science ®Google Scholar
• LingamRScottJTreatment non-adherence in affective disordersActa Psychiatr Scand200210516417211939969
   PubMed Web of Science ®Google Scholar
• PerlisRHAbandoning personalization to get to precision in the pharmacotherapy of depressionWord Psychiatry201615228235
   PubMed Web of Science ®Google Scholar
• El-MallakhRSRobertsRJEl-MallakhPLFindlayLJReynoldsKKPharmacogenomics in psychiatric practiceClin Lab Med20163650752327514465
   PubMed Web of Science ®Google Scholar
• NicholsDEBardesCLDefining “patient-centred medicine”N Eng J Med2012366782783
   Web of Science ®Google Scholar
• GlickIDEllisonJMImproving the practice of clinical psychopharmacotherapy: the process of long-term management for patients and caregiversJ Clin Psychiatry20157673573626132674
   PubMed Web of Science ®Google Scholar
• MathersCDLoncarDProjections of global mortality and burden of disease from 2002 to 2030PLoS Med20063e44217132052
   PubMed Web of Science ®Google Scholar
• CeskovaECurrent pharmacotherapy of depression – focused on multimodal/multifunctional antidepressantsExpert Opin Pharmacother2016171835183727477119
   PubMed Web of Science ®Google Scholar
• FramptonJEVortioxetine: a review in cognitive dysfunction in depressionDrugs2016761675168227807822
   PubMed Web of Science ®Google Scholar
• XuYHackettMCarterGEffect of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysisInt J Neuropsychopharmacol201619115
   Web of Science ®Google Scholar
• ZhangMWHoRCritical appraisal of existing ketamine trials: existing limitations and limited applicability of treatmentAm J Psychiatry2016173431
   PubMed Web of Science ®Google Scholar
• GarayRPZarateCAJrCharpeaudTInvestigational drugs in recent clinical trials for treatment-resistant depressionExpert Rev Neurother201729117
   Google Scholar
• RosenthalRNLingWCasadontePBuprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxoneAddiction20131082141214923919595
   PubMed Web of Science ®Google Scholar
• FavaMMemisogluAThaseMEOpioid modulation with buprenorphine/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trialAm J Psychiatry201617349950826869247
   PubMed Web of Science ®Google Scholar
• PatraSReturn of the psychedelics: psilocybin for treatment resistant depressionAsian J Psychiatr201624515227931907
   PubMed Web of Science ®Google Scholar
• RuckerJJJelenLAFlynnSFrowdeKDYoungAHPsychedelics in the treatment of unipolar mood disorders: a systematic reviewJ Psychopharmacol2016301220122927856684
   PubMed Web of Science ®Google Scholar
• NicholsDEJohnsonMWNicholsCDPsychedelics as medicines: an emerging new paradigmClin Pharmacol Ther201710120921928019026
   PubMed Web of Science ®Google Scholar
• CitromeLBrexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for the newly approved antipsychotic-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Int J Clin Pract20156997899726250067
   PubMed Web of Science ®Google Scholar
• SarrisJMurphyJMischoulonDAdjunctive nutraceuticals for depression: a systematic review and meta-analysesAm J Psychiatry201617357558727113121
   PubMed Web of Science ®Google Scholar
• RaisonCLRutherfordREWoolwineBJA randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkersJAMA Psychiatry201370314122945416
   PubMed Web of Science ®Google Scholar
• EllulPBoyerLGrocLLeboyerMFondGInterleukin-1beta-targeted treatment strategies in inflammatory depression: toward personalized careActa Psych Scand2016134469484
   PubMed Web of Science ®Google Scholar
• BewernickBSchlaepferTEUpdate on neuromodulation for treatment-resistant depression Version 1. F1000Res20154 F1000 Faculty Rev-1389
   Google Scholar
• MurrayCJLopezADEvidence-based health policy-lessons from the Global Burden of Disease StudyScience19962747407438966556
   PubMed Web of Science ®Google Scholar
• CloutierMAigbogunMSGuerinAThe economic burden of schizophrenia in the United States in 2013J Clin Psychiatry20167776477127135986
   PubMed Web of Science ®Google Scholar
• CitromeLThe ABC’s of dopamine receptor partial agonists-aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents outInt J Clin Practice20156912111220
   PubMed Web of Science ®Google Scholar
• DavisRECorrellCUITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomesExpert Rev Neurother20161660161427042868
   PubMed Web of Science ®Google Scholar
• KishimotoTNittaMBorensteinMKaneJMCorrellCULong-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studiesJ Clin Psychiatr201374957965
   PubMed Web of Science ®Google Scholar
• KishimotoTRobenzadehALeuchtCLong-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trialsSchizophr Bull20144019221323256986
   PubMed Web of Science ®Google Scholar
• CruzMPAripiprazole lauroxil (Aristada)An extended-release, long-acting injection for the treatment of schizophreniaP T20164155655927630522
   PubMedGoogle Scholar
• SavitzAJXuHGopalSEfficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority studyInt J Neuropsychopharmacol201619pyw01826902950
   PubMed Web of Science ®Google Scholar
• LewekeFMMuellerJKLangeBRohlederCTherapeutic potential of cannabinoids in psychosisBiol Psychiatry20167960461226852073
   PubMed Web of Science ®Google Scholar
• HenterIDde SousaRTGoldPWBrunoniARZarateCAMachado-VieiraRMood therapeutics: novel approaches for treating depressionExpert Rev Clin Pharmacol20171015316627781556
   PubMed Web of Science ®Google Scholar
• ShimSSHammondsMDKeeBSPotentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine siteEur Arch Psychiatry Clin Neurosci2008258162717901997
   PubMed Web of Science ®Google Scholar
• HashimotoKMalchowBFalkaiPSchmittAGlutamate modulators as potential therapeutic drugs in schizophrenia and affective disordersEur Arch Psychiatry Clin Neurosci201326336737723455590
   PubMed Web of Science ®Google Scholar
• AdamsCEStevensKEEvidence for a role of nicotinic acetylcholine receptors in schizophreniaFront Biosci2007124755477217485411
   PubMed Web of Science ®Google Scholar
• KalkmanHOFeuerbachDModulatory effects of α7 nAChRs on the immune system and its relevance for CNS disordersCell Mol Life Sci2016732511253026979166
   PubMed Web of Science ®Google Scholar